吉西他滨联合卡培他滨治疗蒽环类耐药的转移性乳腺癌的临床疗效和安全性分析

目的分析吉西他滨联合卡培他滨治疗蒽环类耐药的转移性乳腺癌的临床疗效和安全性。方法将2008年6月至2012年6月我院收治的91例对蒽环类耐药的转移性乳腺癌患者为研究对象,并将其随机分为两组,即吉西他滨组45例,给予吉西他滨联合卡培他滨治疗,多西紫杉醇组46例,给予多西紫杉醇联合卡培他滨治疗,21天为1疗程,每疗程进行毒副作用评估,两组均治疗2疗程后对比临床疗效。结果吉西他滨组的总缓解率(44.44%)明显高于多西紫杉醇组(21.74%)(P<0.05);吉西他滨组Ⅲ、Ⅳ度骨髓抑制发生率(17.78%)和Ⅲ、Ⅳ度消化道毒副作用发生率(20.00%)均明显低于多西紫杉醇组(39.13%,43.48%)(P<0.05)。结论吉西他滨联合卡培他滨治疗蒽环类耐药的转移性乳腺癌疗效较多西紫杉醇联合卡培他滨更好,且不良反应的发生率更低,值得临床推广。

Clinical Efficacy and Safety Analysis o Gemcitabine plus Capecitabine in the Treatment of Anthracycline-resistant Metastatic Breast Cancer

Objective To analyze the clinical efficacy and safety of gemcitabine plus capecitabine in the treatment of anthra-cycline-resistant metastatic breast cancer. Methods Ninety-one cases of anthracycline-resistant metastatic breast cancer patients admitted in our hospital between June 2008 and June 2012 were selected and randomly divided into two groups. Forty-five cases in the gemcitabine group were given gemcitabine combined with capecitabine, and 46 cases in the docetaxel group were given docetaxel plus capecitabine treatment. 21 d was taken as a treatment cycle, and the toxic effects were assayed after each cycle. The clinical efficacy were observed and compared between two groups after two treatment cycles. Results The total re-mission rate in the gemcitabine group （44.44%） was significantly higher than that of the paclitaxel group （21.74%） （P〈0.05）. The incidence rates ofⅢdegree,Ⅳdegree of bone marrow suppression （17.78%） and gastrointestinal side effects （20.00%） were both significantly lower in the gemcitabine group than in the docetaxel group （39.13%and 43.48%respectively） （P〈0.05）. Conclusion Treatment with gemcitabine plus capecitabine was more effective than the treatment with docetaxel plus capecitab-ine in treating anthracycline-resistant metastatic breast cancer, with lower incidence rates of adverse reactions. It was worthy of being popularized.